Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.

Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, Chang AR, Inker LA, Kenealy T, Kovesdy CP, Lee BJ, Levin A, Naimark D, Pena MJ, Schold JD, Shalev V, Wetzels JFM, Woodward M, Gansevoort RT, Levey AS, Coresh J.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010008. doi: 10.1681/ASN.2019010008. [Epub ahead of print]

PMID:
31292199
2.

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010009. doi: 10.1681/ASN.2019010009. [Epub ahead of print]

PMID:
31292198
3.

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010007. doi: 10.1681/ASN.2019010007. [Epub ahead of print]

PMID:
31292197
4.

Optimal Use of Biomarkers for Chronic Kidney Disease.

Miller WG, Bachmann LM, Delanghe JR, Inker LA, Jones GRD, Vassalotti JA.

Clin Chem. 2019 May 23. pii: clinchem.2018.299073. doi: 10.1373/clinchem.2018.299073. [Epub ahead of print] No abstract available.

PMID:
31123091
5.

Improving glomerular filtration rate estimation.

Levey AS, Inker LA.

Kidney Int. 2019 May;95(5):1017-1019. doi: 10.1016/j.kint.2019.01.016.

PMID:
31010474
6.

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Heerspink HJL, Coresh J, Gansevoort RT, Inker LA.

Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4. No abstract available.

PMID:
31003622
7.

The Serum Metabolome Identifies Biomarkers of Dietary Acid Load in 2 Studies of Adults with Chronic Kidney Disease.

Rebholz CM, Surapaneni A, Levey AS, Sarnak MJ, Inker LA, Appel LJ, Coresh J, Grams ME.

J Nutr. 2019 Apr 1;149(4):578-585. doi: 10.1093/jn/nxy311.

PMID:
30919901
8.

Serum metabolites associated with dietary protein intake: results from the Modification of Diet in Renal Disease (MDRD) randomized clinical trial.

Rebholz CM, Zheng Z, Grams ME, Appel LJ, Sarnak MJ, Inker LA, Levey AS, Coresh J.

Am J Clin Nutr. 2019 Mar 1;109(3):517-525. doi: 10.1093/ajcn/nqy202.

PMID:
30753252
9.

Serum Metabolomic Alterations Associated with Proteinuria in CKD.

Luo S, Coresh J, Tin A, Rebholz CM, Appel LJ, Chen J, Vasan RS, Anderson AH, Feldman HI, Kimmel PL, Waikar SS, Köttgen A, Evans AM, Levey AS, Inker LA, Sarnak MJ, Grams ME; Chronic Kidney Disease Biomarkers Consortium Investigators.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):342-353. doi: 10.2215/CJN.10010818. Epub 2019 Feb 7.

PMID:
30733224
10.

Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS.

Freed TA, Coresh J, Inker LA, Toal DR, Perichon R, Chen J, Goodman KD, Zhang Q, Conner JK, Hauser DM, Vroom KET, Oyaski ML, Wulff JE, Eiríksdóttir G, Gudnason V, Torres VE, Ford LA, Levey AS.

Clin Chem. 2019 Mar;65(3):406-418. doi: 10.1373/clinchem.2018.288092. Epub 2019 Jan 15.

PMID:
30647123
11.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
12.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
13.

Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.

Zonozi R, Wu A, Shin JI, Secora A, Coresh J, Inker LA, Chang AR, Grams ME.

Mayo Clin Proc. 2019 Jan;94(1):17-26. doi: 10.1016/j.mayocp.2018.08.034.

PMID:
30611444
14.

Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging.

Inker LA, Heerspink HL.

Am J Kidney Dis. 2018 Dec;72(6):771-773. doi: 10.1053/j.ajkd.2018.08.017. No abstract available.

PMID:
30470295
15.

Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD.

Novick TK, Surapaneni A, Shin JI, Ballew SH, Alexander GC, Inker LA, Chang AR, Grams ME.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1886-1888. doi: 10.2215/CJN.08530718. Epub 2018 Nov 8. No abstract available.

PMID:
30409899
16.

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.

Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuilen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A; CKD Prognosis Consortium.

Am J Kidney Dis. 2019 Feb;73(2):206-217. doi: 10.1053/j.ajkd.2018.08.013. Epub 2018 Oct 19.

PMID:
30348535
17.

How best to estimate glomerular filtration rate? Novel filtration markers and their application.

Steubl D, Inker LA.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):398-405. doi: 10.1097/MNH.0000000000000444. Review.

PMID:
30063487
18.

Effects of Body Size and Composition on Sex Differences in Measured GFR in a US Community-Based Older Cohort (MESA-Kidney).

Abraham AG, Shafi T, Tighiouart H, Moseley KF, Post WS, Inker LA, Coresh J, Shlipak MG, Levey AS.

Am J Kidney Dis. 2018 Nov;72(5):767-770. doi: 10.1053/j.ajkd.2018.05.012. Epub 2018 Jul 21. No abstract available.

PMID:
30041875
19.

Biological Variability of Estimated GFR and Albuminuria in CKD.

Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, Xie D, Liu KD, Mifflin TE, Eckfeldt JH, Kimmel PL, Vasan RS, Bonventre JV, Inker LA, Coresh J; Chronic Kidney Disease Biomarkers Consortium Investigators.

Am J Kidney Dis. 2018 Oct;72(4):538-546. doi: 10.1053/j.ajkd.2018.04.023. Epub 2018 Jul 18.

PMID:
30031564
20.

Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation.

Shin JI, Secora A, Alexander GC, Inker LA, Coresh J, Chang AR, Grams ME.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1144-1152. doi: 10.2215/CJN.13811217. Epub 2018 Jul 12.

PMID:
30002224
21.

Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.

Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, Levey AS, Inker LA, Reiser J, Grams ME.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1013-1021. doi: 10.2215/CJN.13631217. Epub 2018 Jun 14.

22.

Serum metabolites are associated with all-cause mortality in chronic kidney disease.

Hu JR, Coresh J, Inker LA, Levey AS, Zheng Z, Rebholz CM, Tin A, Appel LJ, Chen J, Sarnak MJ, Grams ME.

Kidney Int. 2018 Aug;94(2):381-389. doi: 10.1016/j.kint.2018.03.008. Epub 2018 Jun 2.

PMID:
29871777
23.

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.

Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Inker LA, Coresh J, Chang AR, Grams ME.

JAMA Intern Med. 2018 Jul 1;178(7):903-910. doi: 10.1001/jamainternmed.2018.0292.

24.

Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression.

Tin A, Nadkarni G, Evans AM, Winkler CA, Bottinger E, Rebholz CM, Sarnak MJ, Inker LA, Levey AS, Lipkowitz MS, Appel LJ, Arking DE, Coresh J, Grams ME.

J Am Soc Nephrol. 2018 Jul;29(7):1939-1947. doi: 10.1681/ASN.2017101064. Epub 2018 May 18.

25.

Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study.

Coresh J, Inker LA, Sang Y, Chen J, Shafi T, Post WS, Shlipak MG, Ford L, Goodman K, Perichon R, Greene T, Levey AS.

Nephrol Dial Transplant. 2019 May 1;34(5):825-833. doi: 10.1093/ndt/gfy094.

26.

Estimated Glomerular Filtration Rate From a Panel of Filtration Markers-Hope for Increased Accuracy Beyond Measured Glomerular Filtration Rate?

Inker LA, Levey AS, Coresh J.

Adv Chronic Kidney Dis. 2018 Jan;25(1):67-75. doi: 10.1053/j.ackd.2017.10.004. Review.

PMID:
29499889
27.

A Roadmap for Estimated Glomerular Filtration Rate: Where Have We Been, Where Are We Now, and Where Do We Need to Go?

Inker LA.

Adv Chronic Kidney Dis. 2018 Jan;25(1):4-6. doi: 10.1053/j.ackd.2017.10.009. No abstract available.

PMID:
29499885
28.

Assessment of Glomerular Filtration Rate and End-Stage Kidney Disease Risk in Living Kidney Donor Candidates: A Paradigm for Evaluation, Selection, and Counseling.

Inker LA, Koraishy FM, Goyal N, Lentine KL.

Adv Chronic Kidney Dis. 2018 Jan;25(1):21-30. doi: 10.1053/j.ackd.2017.09.002. Review.

PMID:
29499883
29.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

30.

Novel Filtration Markers for GFR Estimation.

Karger AB, Inker LA, Coresh J, Levey AS, Eckfeldt JH.

EJIFCC. 2017 Dec 19;28(4):277-288. eCollection 2017 Dec.

31.

Direct Oral Anticoagulants and Risk of Acute Kidney Injury in Patients With Atrial Fibrillation.

Shin JI, Luo S, Alexander GC, Inker LA, Coresh J, Chang AR, Grams ME.

J Am Coll Cardiol. 2018 Jan 16;71(2):251-252. doi: 10.1016/j.jacc.2017.10.089. No abstract available.

32.

Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C.

Transl Res. 2018 May;195:25-47. doi: 10.1016/j.trsl.2017.12.002. Epub 2017 Dec 12.

33.

In Reply to 'How Valid Are GFR Estimation Results From the CKD-EPI Databases?'

Levey AS, Tighiouart H, Simon AL, Inker LA.

Am J Kidney Dis. 2018 Mar;71(3):447. doi: 10.1053/j.ajkd.2017.11.004. Epub 2017 Dec 26. No abstract available.

PMID:
29287800
34.

Improving Carboplatin Dosing Based on Estimated GFR.

Beumer JH, Inker LA, Levey AS.

Am J Kidney Dis. 2018 Feb;71(2):163-165. doi: 10.1053/j.ajkd.2017.10.005. Epub 2017 Dec 6. No abstract available.

35.

Metabolomic Alterations Associated with Cause of CKD.

Grams ME, Tin A, Rebholz CM, Shafi T, Köttgen A, Perrone RD, Sarnak MJ, Inker LA, Levey AS, Coresh J.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1787-1794. doi: 10.2215/CJN.02560317. Epub 2017 Sep 28.

36.

Strategies for assessing GFR and albuminuria in the living kidney donor evaluation.

Inker LA, Huang N, Levey AS.

Curr Transplant Rep. 2017 Mar;4(1):13-23. doi: 10.1007/s40472-017-0134-0. Epub 2017 Jan 29.

37.

In Reply to 'Newer GFR Estimating Equations Require Validation in Different Populations'.

Levey AS, Tighiouart H, Simon AL, Inker LA.

Am J Kidney Dis. 2017 Oct;70(4):586-587. doi: 10.1053/j.ajkd.2017.06.015. Epub 2017 Aug 11. No abstract available.

PMID:
28807402
38.

Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.

Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.

J Am Heart Assoc. 2017 Jul 19;6(7). pii: e005428. doi: 10.1161/JAHA.116.005428.

39.

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.

Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.

40.

Risk of ESRD and Mortality Associated With Change in Filtration Markers.

Rebholz CM, Inker LA, Chen Y, Liang M, Foster MC, Eckfeldt JH, Kimmel PL, Vasan RS, Feldman HI, Sarnak MJ, Hsu CY, Levey AS, Coresh J; Chronic Kidney Disease Biomarkers Consortium.

Am J Kidney Dis. 2017 Oct;70(4):551-560. doi: 10.1053/j.ajkd.2017.04.025. Epub 2017 Jun 23.

41.

Comparing Newer GFR Estimating Equations Using Creatinine and Cystatin C to the CKD-EPI Equations in Adults.

Levey AS, Tighiouart H, Simon AL, Inker LA.

Am J Kidney Dis. 2017 Oct;70(4):587-589. doi: 10.1053/j.ajkd.2017.04.012. Epub 2017 May 26. No abstract available. Erratum in: Am J Kidney Dis. 2019 Mar 19;:.

PMID:
28552371
42.

Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney.

Foster MC, Levey AS, Inker LA, Shafi T, Fan L, Gudnason V, Katz R, Mitchell GF, Okparavero A, Palsson R, Post WS, Shlipak MG.

Am J Kidney Dis. 2017 Sep;70(3):406-414. doi: 10.1053/j.ajkd.2017.03.021. Epub 2017 May 24.

43.

Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whites: the multiethnic study of atherosclerosis.

Inker LA, Levey AS, Tighiouart H, Shafi T, Eckfeldt JH, Johnson C, Okparavero A, Post WS, Coresh J, Shlipak MG.

Nephrol Dial Transplant. 2018 Mar 1;33(3):417-425. doi: 10.1093/ndt/gfx042.

44.

Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review.

Levey AS, Inker LA.

Clin Pharmacol Ther. 2017 Sep;102(3):405-419. doi: 10.1002/cpt.729. Epub 2017 Jun 5. Review.

PMID:
28474735
45.

Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY; CRIC Study Investigators.

Am J Kidney Dis. 2017 Sep;70(3):337-346. doi: 10.1053/j.ajkd.2017.01.050. Epub 2017 Mar 30.

46.

GFR Evaluation in Living Kidney Donor Candidates.

Levey AS, Inker LA.

J Am Soc Nephrol. 2017 Apr;28(4):1062-1071. doi: 10.1681/ASN.2016070790. Epub 2017 Mar 15.

47.

Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS.

Am J Transplant. 2017 Sep;17(9):2390-2399. doi: 10.1111/ajt.14258. Epub 2017 Mar 30.

48.

Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis.

Inker LA, Coresh J, Sang Y, Hsu CY, Foster MC, Eckfeldt JH, Karger AB, Nelson RG, Liu X, Sarnak M, Appel LJ, Grams M, Xie D, Kimmel PL, Feldman H, Ramachandran V, Levey AS; CKD Biomarkers Consortium.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):69-78. doi: 10.2215/CJN.03660316. Epub 2016 Nov 10.

49.

Effects of Race and Sex on Measured GFR: The Multi-Ethnic Study of Atherosclerosis.

Inker LA, Shafi T, Okparavero A, Tighiouart H, Eckfeldt JH, Katz R, Johnson WC, Dermond N, Tariq Z, Benayache I, Post WS, Coresh J, Levey AS, Shlipak MG.

Am J Kidney Dis. 2016 Nov;68(5):743-751. doi: 10.1053/j.ajkd.2016.06.021. Epub 2016 Aug 20.

PMID:
27555103
50.

A Dynamic Predictive Model for Progression of CKD.

Tangri N, Inker LA, Hiebert B, Wong J, Naimark D, Kent D, Levey AS.

Am J Kidney Dis. 2017 Apr;69(4):514-520. doi: 10.1053/j.ajkd.2016.07.030. Epub 2016 Sep 29.

PMID:
27693260

Supplemental Content

Loading ...
Support Center